APA (7th ed.) Citation

Gavelli, F., Giolitti, F. M., Vidali, M., Montersino, M., Bertoli, M., Molinari, L., . . . Castello, L. M. (2025). Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain. Diagnostics (2075-4418), 15(22), 2851. https://doi.org/10.3390/diagnostics15222851

Chicago Style (17th ed.) Citation

Gavelli, Francesco, et al. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain." Diagnostics (2075-4418) 15, no. 22 (2025): 2851. https://doi.org/10.3390/diagnostics15222851.

MLA (9th ed.) Citation

Gavelli, Francesco, et al. "Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain." Diagnostics (2075-4418), vol. 15, no. 22, 2025, p. 2851, https://doi.org/10.3390/diagnostics15222851.